Day-3 vs. Day-5 Embryo Transfer: What the Latest Research Really Shows

By Emanuela Lazzaroni Tealdi, MSc Senior Embryologist | Lead, ESSI Fertility & Immunology

For many IVF patients, one question comes up again and again during the nerve-wracking wait after an egg retrieval:

“Is it better to transfer my embryos on Day 3 or Day 5?”

For years, the answer in the fertility industry seemed simple. Many clinics moved uniformly toward Day-5 blastocyst transfers because blastocysts tend to implant at higher rates.

But recent scientific research reveals that the answer is far more complex than a rigid clinic policy. New studies published between 2024 and 2026 suggest that the “best” strategy is not universal—it depends entirely on the unique biology of the individual patient.

Here is a look at the science behind embryo development and what the latest data means for your IVF journey.

Understanding the Difference: Day-3 vs. Day-5 Embryos

During IVF, once an egg is fertilized, the embryo develops in the controlled environment of the laboratory.

• Day 3 (Cleavage Stage): By the third day, a healthy embryo is typically composed of about 6 to 8 cells. At this stage, it is called a cleavage-stage embryo.

• Day 5 (Blastocyst Stage): By the fifth day, embryos that continue developing reach the blastocyst stage. This is a highly advanced structure where cells have begun differentiating into two major components: the inner cell mass (which will form the fetus) and the trophectoderm (which will later form the placenta).

Extending the embryo culture to Day 5 allows embryologists to observe development over a longer period, enabling them to select the embryos that appear to have the strongest developmental potential.

However, this extended culture introduces a critical limitation: Some embryos that might have successfully implanted in the natural environment of the uterus may arrest (stop developing) in the artificial environment of the laboratory before ever reaching Day 5.

What the Latest Research is Showing

Several recent, high-level studies have revisited the Day-3 versus Day-5 debate, revealing nuanced insights:

• Higher Implantation per Transfer: A 2026 meta-analysis led by Glujovsky and colleagues compared cleavage-stage and blastocyst transfers. They found that blastocyst transfers were associated with higher live birth rates per transfer. In practical terms, when a Day-5 blastocyst is transferred, the immediate chance of implantation is generally higher compared to a Day-3 embryo. Additional evidence from a 2025 cohort study by Hamzaoğlu and colleagues analyzing over 6,000 frozen cycles supported this strong implantation potential for blastocysts.

• The “Cumulative” Catch: However, the picture changes when looking at the “big picture.” A 2024 randomized controlled trial published in the BMJ by Cornelisse and colleagues looked at cumulative live birth rates (the total success rate from a single egg retrieval, including all fresh and frozen transfers). The study found no significant difference in cumulative live birth rates between the two approaches.

This is a profound finding. It suggests that some fragile embryos that arrested during extended culture in the laboratory might have resulted in a healthy pregnancy if they had been transferred to the uterus earlier at the cleavage stage.

Simply put: the laboratory incubator, even with state-of-the-art technology, is not identical to the natural, nurturing environment of the human uterus.

The Key Concept: Selection vs. Biology

One of the most vital concepts emerging from this research is the difference between a biological advantage and a selection advantage.

Leaving an embryo in the lab until Day 5 does not magically make it stronger. Instead, blastocyst culture acts as a powerful selection tool, or filter. Embryos that successfully reach the blastocyst stage have proven their developmental competence, allowing embryologists to pick the best candidate for transfer.

However, because it is a filter, some viable embryos could be lost during the extended wait.

Why Personalization Matters in IVF

At ESSI Fertility & Immunology, we firmly believe that fertility care should never follow a rigid, “one-size-fits-all” protocol. IVF decisions must be highly individualized based on the biological context of each patient.

Several crucial factors influence whether a Day-3 or Day-5 strategy is optimal for you:

• Maternal Age & Ovarian Reserve: Older patients or those with diminished reserve may benefit from early transfer.

• Number of Embryos Available: For patients with a high number of embryos, extended culture to Day 5 helps identify the strongest candidates. For patients with very few embryos, transferring on Day 3 may preserve fragile opportunities that could otherwise be lost in the lab.

• Previous IVF Outcomes & Lab Development Patterns: How your embryos have historically behaved in culture dictates our strategy.

• Genetic Testing (PGT-A): If genetic testing is planned, embryos must reach the blastocyst stage to be safely biopsied.

The ESSI Perspective: Beyond the Embryo

Successful implantation is never determined by embryo quality alone. It is the result of a delicate, complex interaction between embryo development, uterine receptivity, and the maternal immune environment.

At ESSI Fertility & Immunology, we approach your care through an integrated lens. We combine elite embryology, advanced reproductive medicine, and specialized reproductive immunology to ensure that we are not only selecting the right embryo, but also transferring it into a uterine environment that is truly prepared to embrace it.

The debate between Day-3 and Day-5 is not about which option is universally better. It is about which strategy maximizes the chance of a healthy baby for you. Sometimes, preserving your possibilities is just as important as selecting the strongest embryo.

References:

• Glujovsky D et al. Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology cycles. Updated meta-analysis, 2026.

• Cornelisse S et al. Cleavage-stage versus blastocyst-stage embryo transfer and cumulative live birth rate. BMJ. 2024.

• Hamzaoğlu N et al. Comparison of frozen-thawed cleavage-stage and blastocyst-stage embryo transfer outcomes. 2025 cohort study.